Neuronetics TMS patient access expands through Lucet Health policy update

Neuronetics announced criteria changes by Lucet Health that increase access for patients with depression to receive transcranial magnetic stimulation, TMS, such as NeuroStar Advanced Therapy. The policy update reduces the number of antidepressant medication attempts from four down to two prior to TMS eligibility. “I am pleased to witness the collective efforts leading to improved access to mental health coverage,” stated Keith Sullivan, President and CEO of Neuronetics, Inc. “We commend Lucet Health for recognizing the importance of ensuring that individuals can access proven treatments like NeuroStar earlier in their path towards wellness.” Lucet Health is a behavioral health organization that works with large insurance carriers across the country. Its policies impact approximately 9 million covered lives. The updated TMS criteria are effective as of February 1, 2024.